NF-KB p65 Antibody (YA6412)

Cat. No.: HY-P86720: Data Sheet COA
SDS
User Guide for Antibodies
FAQs
Technical Support

NF-KB p65 Antibody (YA6412) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to NF-KB p65.

For research use only. We do not sell to patients.

Size	Stock	Quantity
10 μL	In-stock	Estimated Time of Arrival: December 31
50 μL	In-stock	Estimated Time of Arrival: December 31
100 μL	In-stock	Estimated Time of Arrival: December 31
250 μL	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

WB: Western Blot;
IHC-P: Immunohistochemistry-Paraffin;
IHC-F: Immunohistochemistry-Frozen;
ICC/IF: Immunocytochemistry/Immunofluorescence;
IF-Tissue: Immunofluorescence-Tissue;
mIHC: Multiplex Immunohistochemical;
IP: Immunoprecipitation;
ChIP: Chromatin Immunoprecipitation;
FC: Flow Cytometry;
ELISA: Enzyme Linked Immunosorbent Assay

Product Detail
Background
Documentation

Description

NF-KB p65 Antibody (YA6412) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to NF-KB p65.

Host

Mouse

Clonality

Monoclonal

Molecular Weight

Predicted band size: 61 kDa

Species Reactivity

Human, Mouse, Rat

SwissProt ID

Q04206

Gene ID

5970 [NCBI]

Immunogen

KLH conjugated synthetic peptide derived from human NFKB p65

Application &
Dilution Ratio

Application	Dilution Ratio
WB WB: Western Blot	1:1000-5000
IHC-P IHC-P: Immunohistochemistry-Paraffin	1:500-2000
IHC-F IHC-F: Immunohistochemistry-Frozen	1:500-2000
ICC/IF ICC/IF: Immunocytochemistry/Immunofluorescence	1:500-2000

Purity	affinity purified.	Conjugation	Non-conjugated
Modification	Unmodified	Isotype	IgG1

Appearance

Liquid

Formulation

Supplied in 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage & Stability

Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.

Shipping

Shipping with blue ice.

Background

Function：NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The heterodimeric RELA-NFKB1 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. The NF-kappa-B heterodimeric RELA-NFKB1 and RELA-REL complexes, for instance, function as transcriptional activators. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. The inhibitory effect of I-kappa-B on NF-kappa-B through retention in the cytoplasm is exerted primarily through the interaction with RELA. RELA shows a weak DNA-binding site which could contribute directly to DNA binding in the NF-kappa-B complex. Besides its activity as a direct transcriptional activator, it is also able to modulate promoters accessibility to transcription factors and thereby indirectly regulate gene expression. Associates with chromatin at the NF-kappa-B promoter region via association with DDX1. Essential for cytokine gene expression in T-cells (PubMed:15790681). The NF-kappa-B homodimeric RELA-RELA complex appears to be involved in invasin-mediated activation of IL-8 expression. Key transcription factor regulating the IFN response during SARS-CoV-2 infection (PubMed:33440148)

Subcellular Localization：Nucleus,Cytoplasm

Isoforms & Post-Translational Modification：Q04206 has four isomers: Q04206-1: 60219 Da (predicted); Q04206-2: 58807 Da (predicted); Q04206-3: 59068 Da (predicted); Q04206-4: 59910 Da (predicted).
Ubiquitinated by RNF182, leading to its proteasomal degradation (PubMed:31432514)丨Monomethylated at Lys-310 by SETD6 (PubMed:21515635)丨Phosphorylation at Ser-311 disrupts the interaction with EHMT1 and promotes transcription factor activity (By similarity)丨Phosphorylation at Ser-75 by herpes simplex virus 1/HHV-1 inhibits NF-kappa-B activation丨Reversibly acetylated; the acetylation seems to be mediated by CBP, the deacetylation by HDAC3 and SIRT2丨S-nitrosylation of Cys-38 inactivates the enzyme activity丨Sulfhydration at Cys-38 mediates the anti-apoptotic activity by promoting the interaction with RPS3 and activating the transcription factor activity丨Sumoylation by PIAS3 negatively regulates DNA-bound activated NF-kappa-B丨Proteolytically cleaved within a conserved N-terminus region required for base-specific contact with DNA in a CPEN1-mediated manner, and hence inhibits NF-kappa-B transcriptional activity (PubMed:18212740)

Subunit：Component of the NF-kappa-B p65-p50 complex

Synonyms

TF65_HUMAN; Transcription factor p65; RELA; Nuclear factor NF-kappa-B p65 subunit; Nuclear factor of kappa light polypeptide gene enhancer in B-cells 3; NFKB3; RELA proto-oncogene, NF-kB subunit; p65; CMCU; NFKB3; AIF3BL3; NF-kB p65/RelA; NFκB-p65; NFκB p65; NF κB-p65; NFκBp65;

Documentation

Select Batch:

Data Sheet (231 KB) SDS (252 KB)

COA (206 KB)

User Guide for Antibodies (1077 KB)